MX2013008367A - Firmas de esxpresion genetica de cancer de colon y metodos de uso. - Google Patents

Firmas de esxpresion genetica de cancer de colon y metodos de uso.

Info

Publication number
MX2013008367A
MX2013008367A MX2013008367A MX2013008367A MX2013008367A MX 2013008367 A MX2013008367 A MX 2013008367A MX 2013008367 A MX2013008367 A MX 2013008367A MX 2013008367 A MX2013008367 A MX 2013008367A MX 2013008367 A MX2013008367 A MX 2013008367A
Authority
MX
Mexico
Prior art keywords
colon cancer
methods
gene expression
cancer gene
expression signatures
Prior art date
Application number
MX2013008367A
Other languages
English (en)
Spanish (es)
Inventor
Denis Paul Harkin
Vitali Proutski
Julie Black
Peter Kerr
Richard Kennedy
Andreas Winter
Timothy Davison
Max Bylesjo
Vadim Farztdinov
Claire Wilson
Robert James Holt
Original Assignee
Almac Diagnostics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Diagnostics Ltd filed Critical Almac Diagnostics Ltd
Publication of MX2013008367A publication Critical patent/MX2013008367A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2013008367A 2011-01-25 2012-01-25 Firmas de esxpresion genetica de cancer de colon y metodos de uso. MX2013008367A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161435922P 2011-01-25 2011-01-25
PCT/US2012/022594 WO2012103250A2 (en) 2011-01-25 2012-01-25 Colon cancer gene expression signatures and methods of use

Publications (1)

Publication Number Publication Date
MX2013008367A true MX2013008367A (es) 2013-08-12

Family

ID=46581385

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008367A MX2013008367A (es) 2011-01-25 2012-01-25 Firmas de esxpresion genetica de cancer de colon y metodos de uso.

Country Status (14)

Country Link
US (1) US10196691B2 (enExample)
EP (1) EP2668296B1 (enExample)
JP (1) JP2014509189A (enExample)
KR (1) KR20140006898A (enExample)
CN (1) CN103403543B9 (enExample)
AU (1) AU2012209074A1 (enExample)
BR (1) BR112013018924A2 (enExample)
CA (1) CA2825218A1 (enExample)
EA (1) EA201391074A1 (enExample)
IL (1) IL227643A0 (enExample)
MX (1) MX2013008367A (enExample)
SG (1) SG192108A1 (enExample)
WO (1) WO2012103250A2 (enExample)
ZA (1) ZA201305024B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101866401B1 (ko) 2010-04-05 2018-06-11 프로그노시스 바이오사이언스, 인코포레이티드 공간적으로 엔코딩된 생물학적 검정
US20190300945A1 (en) 2010-04-05 2019-10-03 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
US20130074201A1 (en) * 2011-09-16 2013-03-21 The Johns Hopkins University Cancer-specific genetic rearrangements
EP3901280B1 (en) * 2012-10-17 2025-03-12 10x Genomics Sweden AB Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
CN111500680B (zh) 2013-06-25 2024-04-16 普罗格诺西斯生物科学公司 检测样品中生物靶标的空间分布的方法和系统
US9652722B1 (en) * 2013-12-05 2017-05-16 The Mathworks, Inc. Methods and systems for robust supervised machine learning
ES2713240T3 (es) * 2014-02-17 2019-05-20 Ventana Med Syst Inc Proteína asociada a vesícula que interacciona con G-alfa (GIV) como marcador predictivo en cáncer colorrectal de estadio II
EP3129509B1 (en) * 2014-04-10 2020-06-17 Bio-Marcare Technologies Ltd. Methods and kits for identifying pre-cancerous colorectal polyps and colorectal cancer
EP4321627A3 (en) 2015-04-10 2024-04-17 10x Genomics Sweden AB Spatially distinguished, multiplex nucleic acid analysis of biological specimens
CN108020672A (zh) * 2016-11-03 2018-05-11 中国医学科学院基础医学研究所 检测rhbdd1蛋白的elisa方法及试剂盒
WO2018107023A1 (en) * 2016-12-08 2018-06-14 Dana-Farber Cancer Institute, Inc. Metabolic profiling of fixed samples
CN107158388B (zh) * 2017-07-11 2021-03-23 上海市第一人民医院 MIIP pS303阻断剂在制备抗肿瘤药物中的应用
DK3743534T3 (da) 2018-01-22 2022-06-20 Liquid Biopsy Res Llc Fremgangsmåde til påvisning af coloncancer og behandlingsovervågning
AU2019252672B2 (en) * 2018-04-12 2025-08-14 Board Of Regents, The University Of Texas System Biomarker for detecting cancer
JP2020028278A (ja) * 2018-08-24 2020-02-27 国立大学法人九州大学 被検体に生じるイベントを予測するための判別器の生成方法、及び前記判別器を用いた被検体の層別化方法
CN111321220A (zh) * 2018-12-14 2020-06-23 中国医学科学院肿瘤医院 用于检测直肠癌放化疗敏感性的组合物、微阵列和计算机系统
CN110079607B (zh) * 2019-04-04 2022-08-02 陕西师范大学 一种引物组、检测血液样品种属的方法及应用
EP3976820A1 (en) 2019-05-30 2022-04-06 10X Genomics, Inc. Methods of detecting spatial heterogeneity of a biological sample
EP4025692A2 (en) 2020-06-02 2022-07-13 10X Genomics, Inc. Nucleic acid library methods
EP4600376A3 (en) 2020-06-02 2025-10-22 10X Genomics, Inc. Spatial transcriptomics for antigen-receptors
EP4421186B1 (en) 2020-06-08 2025-08-13 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
EP4172621A1 (en) * 2020-06-30 2023-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
CN111951883A (zh) * 2020-08-04 2020-11-17 广东省第二人民医院(广东省卫生应急医院) 一种特征mRNA表达谱组合及结肠癌早期预测方法
AU2022256363A1 (en) * 2021-04-14 2023-11-02 Amgen Inc. Automated outlier removal for multivariate modeling
CN115786518A (zh) * 2022-11-29 2023-03-14 广东医科大学附属医院 嗅素结构域家族蛋白4(olfm4)在结肠癌检测产品中的应用
US20240327927A1 (en) * 2023-03-27 2024-10-03 Immunis.Ai, Inc. Active surveillance and risk stratification for prostate cancer
CN119372311A (zh) * 2024-09-30 2025-01-28 东南大学 基于成纤维细胞相关基因的结肠癌预后和治疗抵抗预测模型的构建方法和应用
CN120009551B (zh) * 2025-02-27 2025-08-15 西南医科大学 剪接因子wbp11及其抑制剂的用途、预防或治疗结直肠癌的药物

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0155950B1 (en) 1983-09-02 1990-01-17 Molecular Biosystems, Inc. Oligonucleotide polymeric support system
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
ATE138106T1 (de) 1988-07-20 1996-06-15 David Segev Verfahren zur amplifizierung und zum nachweis von nukleinsäuresequenzen
US5219727A (en) 1989-08-21 1993-06-15 Hoffmann-Laroche Inc. Quantitation of nucleic acids using the polymerase chain reaction
US5427930A (en) 1990-01-26 1995-06-27 Abbott Laboratories Amplification of target nucleic acids using gap filling ligase chain reaction
US5554501A (en) 1992-10-29 1996-09-10 Beckman Instruments, Inc. Biopolymer synthesis using surface activated biaxially oriented polypropylene
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
AU2360195A (en) 1994-05-05 1995-11-29 Beckman Instruments, Inc. Oligonucleotide repeat arrays
ES2168380T3 (es) 1994-07-15 2002-06-16 Organon Teknika Bv Utilizacion de arn polimerasa para mejorar un procedimiento de amplificacion de acido nucleico.
AT402203B (de) 1995-06-13 1997-03-25 Himmler Gottfried Dipl Ing Dr Verfahren zur transkriptionsfreien amplifizierung von nucleinsäuren
US5716784A (en) 1996-02-05 1998-02-10 The Perkin-Elmer Corporation Fluorescence detection assay for homogeneous PCR hybridization systems
AU730633B2 (en) 1996-05-29 2001-03-08 Phillip Belgrader Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
US5985567A (en) 1997-08-15 1999-11-16 Beckman Coulter, Inc. Hybridization detection by pretreating bound single-stranded probes
US6013789A (en) 1998-02-20 2000-01-11 Beckman Coulter, Inc. Covalent attachment of biomolecules to derivatized polypropylene supports
AU2001252945A1 (en) 2000-03-24 2001-10-08 Corixa Corporation Compositions and methods for therapy and diagnosis of colon cancer
AU2003209340A1 (en) 2002-01-18 2003-09-02 Bristol-Myers Squibb Company Predictor sets for tyrosine kinase pathways
EP2305813A3 (en) * 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US20040146921A1 (en) 2003-01-24 2004-07-29 Bayer Pharmaceuticals Corporation Expression profiles for colon cancer and methods of use
WO2005054508A2 (en) 2003-12-01 2005-06-16 Ipsogen Gene expression profiling of colon cancer by dna microarrays and correlation with survival and histoclinical parameters
JP2008504803A (ja) 2004-01-09 2008-02-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 遺伝子発現の細胞型特異的パターン
WO2005083128A2 (en) 2004-02-25 2005-09-09 University Of South Florida Methods for predicting cancer outcome and gene signatures for use therein
US20060195266A1 (en) 2005-02-25 2006-08-31 Yeatman Timothy J Methods for predicting cancer outcome and gene signatures for use therein
CA2569079A1 (en) * 2004-06-03 2005-12-15 The Johns Hopkins University Methods of screening for cell proliferation or neoplastic disorders
JP2008518610A (ja) 2004-11-03 2008-06-05 アルマック ダイアグノスティックス リミテッド トランスクリプトームマイクロアレイ技法およびそれを使用する方法
US8249814B2 (en) 2005-10-21 2012-08-21 Genenews Inc. Method, computer readable medium, and system for determining a probability of colorectal cancer in a test subject
DK1974058T3 (da) * 2006-01-11 2014-09-01 Genomic Health Inc Genekspressionsmarkører til prognosticering af kolorektal cancer
WO2007112330A2 (en) 2006-03-24 2007-10-04 Diadexus, Inc. Compositions and methods for detection, prognosis and treatment of colon cancer
US20100261169A1 (en) 2007-01-29 2010-10-14 Shira Wallach Novel nucleotide and amino acid sequences, and methods of use thereof for diagnosis
NZ562237A (en) 2007-10-05 2011-02-25 Pacific Edge Biotechnology Ltd Proliferation signature and prognosis for gastrointestinal cancer
JP5588970B2 (ja) * 2008-05-27 2014-09-10 ダコ・デンマーク・エー/エス ハイブリダイゼーション組成物及び方法
WO2010060055A1 (en) 2008-11-21 2010-05-27 Duke University Predicting cancer risk and treatment success

Also Published As

Publication number Publication date
AU2012209074A1 (en) 2013-07-11
EP2668296A2 (en) 2013-12-04
SG192108A1 (en) 2013-08-30
CN103403543B9 (zh) 2017-05-17
EP2668296A4 (en) 2015-09-02
IL227643A0 (en) 2013-09-30
JP2014509189A (ja) 2014-04-17
ZA201305024B (en) 2014-03-26
EA201391074A1 (ru) 2013-12-30
WO2012103250A2 (en) 2012-08-02
CA2825218A1 (en) 2012-08-02
EP2668296B1 (en) 2018-08-15
CN103403543A (zh) 2013-11-20
KR20140006898A (ko) 2014-01-16
US20140094379A1 (en) 2014-04-03
NZ612471A (en) 2015-11-27
BR112013018924A2 (en) 2018-05-08
WO2012103250A3 (en) 2012-10-11
US10196691B2 (en) 2019-02-05
CN103403543B (zh) 2016-11-09

Similar Documents

Publication Publication Date Title
EP2668296A2 (en) Colon cancer gene expression signatures and methods of use
MX341734B (es) Biomarcadores para la prediccion de la eficacia de una inmunoterapia contra el cancer.
MX346973B (es) Anticuerpos especificos de tumores y usos para los mismos.
CO7350624A2 (es) Inhibidores de la tirosina-quinasa de bruton
CY1118001T1 (el) Νεες ctla4-ig προσκολλητινες
MX356986B (es) Metodo para detectar aductos de nucleosomas.
IL245113A0 (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CY1121185T1 (el) Αδενοϊος που εκφραζει fas-χιμαιρα και χρηση αυτης σε μεθοδους θεραπειας καρκινου
CR20120406A (es) Identificación de mutación lkb1 como un biomarcador predictivo para sensibilidad a inhibidores de tor cinasa
WO2012006447A3 (en) Gene signatures for cancer prognosis
CL2017001110A1 (es) Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva
EA201171367A1 (ru) Винилиндазолильные соединения
BR112014011925A2 (pt) mutações no receptor notch humano e seu uso
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
BR112015010740A2 (pt) Agentes para tratamento de doenças cancerosas expressando claudina
MX2015004610A (es) Metodo para diagnostico, pronostico y tratamiento de metastasis de cancer de prostata usando c-maf.
MX2014006404A (es) Metodos y kits para el pronostico del cancer colorrectal.
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
GT201500249A (es) Terapia de combinación
EA201590650A1 (ru) Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
AR090129A1 (es) Oligonucleotidos para la modulacion de la expresion genica y sus usos
WO2013028554A3 (en) Gene signatures for lung cancer prognosis and therapy selection
CL2013003324A1 (es) Composicion que comprende quimioterapia con paclitaxel y carboplatino y un oligonucleotido anti-clusterina; uso de la composición para el tratamiento de un paciente humano que padece cancer de pulmón.
MX2015002749A (es) Metodo diagnostico y terapeutico para el cancer dirigido a moleculas expresadas en celulas madre cancerosas.
AR087363A1 (es) Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres